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Background: Over the last few years transcriptome sequencing (RNA-Seq) has almost completely taken over
microarrays for high-throughput studies of gene expression. Currently, the most popular use of RNA-Seq is to
identify genes which are differentially expressed between two or more conditions. Despite the importance of Gene
Set Analysis (GSA) in the interpretation of the results from RNA-Seq experiments, the limitations of GSA methods
developed for microarrays in the context of RNA-Seq data are not well understood.
Results: We provide a thorough evaluation of popular multivariate and gene-level self-contained GSA approaches
on simulated and real RNA-Seq data. The multivariate approach employs multivariate non-parametric tests
combined with popular normalizations for RNA-Seq data. The gene-level approach utilizes univariate tests designed
for the analysis of RNA-Seq data to find gene-specific P-values and combines them into a pathway P-value using
classical statistical techniques. Our results demonstrate that the Type I error rate and the power of multivariate tests
depend only on the test statistics and are insensitive to the different normalizations. In general standard multivariate
GSA tests detect pathways that do not have any bias in terms of pathways size, percentage of differentially
expressed genes, or average gene length in a pathway. In contrast the Type I error rate and the power of
gene-level GSA tests are heavily affected by the methods for combining P-values, and all aforementioned biases
are present in detected pathways.
Conclusions: Our result emphasizes the importance of using self-contained non-parametric multivariate tests for
detecting differentially expressed pathways for RNA-Seq data and warns against applying gene-level GSA tests,
especially because of their high level of Type I error rates for both, simulated and real data.Background
Over the last few years transcriptome deep sequencing
(RNA-Seq) has almost completely taken over micro-
arrays for high-throughput studies of gene expression. In
contrast to microarrays, RNA-Seq technology quantifies
expression in counts of transcript reads mapped to a
genomic region [1,2]. These read counts are integer
numbers ranging from zero to millions. This is why ap-
proaches that were developed for the analysis of micro-
array data are generally not applicable to the analysis of
RNA-Seq data: microarray approaches model the gene
expression by continuous distributions. The most com-
mon use of RNA-Seq has been identifying genes that
are differentially expressed (DE) between two or more* Correspondence: gvglazko@uams.edu
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article, unless otherwise stated.conditions. Typically, gene counts are modeled using
Poisson or Negative Binomial (NB) distribution, and se-
veral commonly used software packages such as edgeR
[3], DESeq [4], and SamSeq [5] adapted for RNA-Seq,
are freely available. Recently it was suggested to trans-
form RNA-Seq count data prior to the analysis and
apply normal-based microarray-like statistical methods,
e.g. the limma pipeline [6] to RNA-Seq data [7].
Similarly, a decade ago, the focus of microarrays data
analysis was also on finding DE genes. The methods
for microarray data were dominated by univariate two-
sample statistical tests for finding DE genes. However, it
was quickly recognized that (1) biologically relevant
genes with small changes in expression are almost
always absent in the list of statistically significant DE
genes, detected using two-sample tests with the correc-
tion for multiple testing [8], and (2) because genes do
not work in isolation, statistical tests need to account forntral Ltd. This is an Open Access article distributed under the terms of the
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address the shortcomings of gene-level analyses, concep-
tually new approaches were suggested which operated
with gene sets, i.e. treating a gene set as an expression
unit. Importantly, differentially expressed gene sets (such
as biological pathways) incorporate existing biological
knowledge into the analysis, thus providing more ex-
planatory power than a long list of seemingly unrelated
genes [9]. To date many methodologies for testing dif-
ferential expression of gene sets have been suggested
and are collectively named Gene Set Analysis (GSA) ap-
proaches [10-13].
GSA approaches can be either competitive or self-
contained. Competitive approaches compare a gene set
against its complement that contains all genes except the
genes in the set, and self-contained approaches test
whether a gene set is differentially expressed between two
phenotypes [14,15]. Another technique that incorporates
biological knowledge into the analysis, that requires a list
of pre-selected DE genes to proceed, is the gene set over-
representation analysis. Here, a set of pre-selected sig-
nificantly DE genes is tested for over-representation in
annotated gene sets such as Gene Ontology (GO) cate-
gories or Kyoto Encyclopedia of genes and genomes
(KEGG) using standard statistical tests for enrichment
[16]. A shortcoming of the over-representation approach
is that it still requires a preselected gene list and genes
with small changes may not be accounted for [10].
The first competitive GSA test for microarray data
analysis (Gene Set Enrichment Analysis, GSEA [8]) was
developed a decade ago, and in the last decade pathways
analysis for microarray data has become a method of
choice for explaining the biology underlying the experi-
mental results [10,17,18]. One would expect there to be
plenty of GSA approaches suitable for RNA-Seq data
analysis, yet well-tested and justified methods are scarce.
The first approach, adapting GSA for RNA-Seq data,
was suggested by Young and colleagues [19]. They
developed GOseq, a GO categories over-representation
analysis that accounts for the over-detection of GO cate-
gories enriched with long and highly expressed genes in
RNA-Seq data. Next, a non-parametric competitive GSA
approach named GSVA (Gene Set Variation Analysis)
has demonstrated highly correlated results between
microarrays and RNA-Seq sets of samples of lym-
phoblastoids, cell lines which have been profiled by both
technologies [20]. Shortly after, Wang and Cairns [21]
suggested SeqGSEA, an adaptation of GSEA to RNA-
Seq data. All of the aforementioned approaches are not
without inherent biases: GO-Seq results depend on the
methods selected for finding DE genes [19], and com-
petitive approaches (in particular GSEA) are influenced
by the filtering of the data and can even increase their
power by the addition of unrelated data and noise [22].The discussion about the possibility of using self-
contained gene-level tests for GSA for microarrays data
was on-going for a long time: such tests are straightfor-
ward and can be easily designed [11]. Some authors (e.g.
[23,24]) were recommending to use gene-level tests for
GSA. At the same time, because these tests are not truly
multivariate and have much lower power compared to
multivariate approaches, some authors [18] were advising
against the application of gene-level tests for GSA. In a re-
cent publication gene-level tests were claimed to be the
first method of choice for GSA of RNA-Seq data [25]. In
the simulation study expression data (reads) were taken
from a multivariate normal distribution [25]. Because
reads are integer numbers and are usually modeled using
Poisson or Negative Binomial distribution, the simulation
results of the study [25] may be inconclusive.
Thus far, except for gene-level GSA tests [25], the
power and Type I error rates of self-contained approa-
ches were not examined in the context of RNA-Seq
data. Here we study the performance of several self-
contained GSA approaches – multivariate and gene-
level – for finding differentially expressed pathways in
RNA-Seq data. The goals of our study are to: 1) de-
scribe several non-parametric multivariate GSA approa-
ches developed for microarray data [18,26] that do not
have distributional assumptions and are readily applicable
to RNA-Seq data given proper normalization; 2) evaluate
the performance of the four most commonly used RNA-
Seq normalization approaches in combination with the
aforementioned non-parametric multivariate GSA; 3) de-
scribe how univariate tests specifically designed for finding
DE genes in RNA-Seq data can be extended to gene-level
GSA tests by using procedures for combining genes
P-values into a pathway P-value (Fisher’s combining prob-
abilities Method (FM) [27], Stouffer’s Method (SM) [28]
and the soft thresholding Gamma Method (GM) [25]); 4)
evaluate the performance of the three most commonly
used univariate tests for the analysis of RNA-Seq data
(edgeR, DESeq, and eBayes) in combination with ap-
proaches for combining genes P-values into a pathway
P-value; and 5) provide comparative power and Type I
error rate analyses for multivariate and gene-level GSA
tests.
In addition we evaluate whether non-parametric
multivariate GSA approaches with different norma-
lizations as well as gene-level GSA tests are prone to
different types of selection biases. We check all GSA ap-
proaches for over-detection of pathways enriched with
long genes. This bias was shown to exist in gene set
over-representation analysis [19], but it is currently un-
known whether it exists in GSA approaches. We also
check whether GSA approaches over-detect pathways
with small (large) number of genes and small (large) per-
centage of differentially expressed genes. In conclusion,
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contained GSA approaches given RNA-Seq data.
In what follows we briefly describe several multivariate
non-parametric tests [18,26]. We also consider the mul-
tivariate ROAST test [29] designed for microarray data
but, given proper normalization, also applicable to RNA-
Seq. Then we discuss approaches for combining P-values
from univariate tests, such as edgeR, DESeq, and eBayes,
specifically designed for the analysis of differential gene
expression using RNA-Seq data sets into a pathway
P-value. Approaches for RNA-Seq data normalizations
together with a brief description of biological and simu-
lated data used for testing purposes are presented in the
end of this section.
Methods
Hypothesis testing
Statistically speaking the problem of finding differentially
expressed pathways is a hypothesis testing problem.
Consider two different phenotypes with n1 samples of
measurements of p genes for the first and n2 samples of
measurement of the same p genes for the second phe-
notype. Let the two p-dimensional random vectors of
measurements X = (X1,…, Xn1) and Y = (Y1,…, Yn2) be
independent and identically distributed with the distri-
bution functions F, G, mean vectors μx, μy and p × p co-
variance matrices Sx , Sy. We consider the problem of
testing the general hypothesis H0: F =G against an alter-
native H1: F ≠G, or a restricted hypothesis H0: μx = μy
against an alternative H1: μx ≠ μy, depending on the test
statistic.
Multivariate tests
We adopted the multivariate generalization of the Wald-
Wolfowitz (WW) and Kolmogorov-Smirnov (KS) tests
[18] as suggested by Friedman and Rafsky [26]. These two
tests were not used before in the context of pathway ana-
lysis with RNA-Seq data. The multivariate generalization
is based on the minimum spanning tree (MST) of the
complete network (graph) generated from gene expression
data.
For an edge-weighted graph G(V,E) where V is the set
of vertices and E is the set of edges, the MST is defined
as the acyclic subset T⊆ E that connects all vertices in V
and whose total length ∑i,j∈ Td(vi, vj) is minimal. For the
p-dimensional observations X and Y, an edge-weighted
complete graph can be constructed with N nodes and N
(N-1)/2 edge weights estimated by the Euclidean (or any
other) distance measure between pairs of points in Rp.
The MST of such graph connects all N nodes (vertices)
that are close in Rp with N-1 nodes.
For a univariate two-sample test (p = 1), the KS test be-
gins by sorting the N = n1 + n2 observations in ascending
order. Then, observations are ranked and the quantitydi = ri/n1 − si/n2 is calculated where ri (si) is the number of
observations in X (Y) ranked lower than i, 1 ≤ i ≤N.
The test statistic is the maximal absolute difference
D =maxi|di|, and H0: μx = μy is rejected for large D. The
multivariate generalization of the KS test ranks multiva-
riate observations based on their MST to obtain the
strong relation between observations differences in ranks
and their distances in Rp. The MST is rooted at a node
with the largest geodesic distance, and then the nodes are
ranked in the high directed preorder (HDP) traversal of
the tree [26]. Then, the test statistic D is found for the
ranked nodes. The null distribution of D is estimated
using samples label permutations, and H0: μx = μy is
rejected for a large observed D [26].
For a univariate two-sample test (p = 1), the WW test
begins by sorting the N = n1 + n2 observations in ascen-
ding order. Then, each observation is replaced by its
phenotype label (X or Y), and the number of runs (R) is
calculated where R is a consecutive sequence of identical
labels. In the multivariate generalization of the WW test,
all edges of MST incident between nodes belonging to
different phenotype labels (X and Y) are removed, and
the number of the remaining disjoint subtrees (R) is
calculated. The permutation distribution of the standar-
dized number of subtrees is asymptotically normal, and
H0: μx = μy is rejected for a small number of subtrees [26].
We consider two other multivariate test statistics
based on their high power and popularity. N-statistic
[30,31] tests the most general hypothesis H0: F =G
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Here we consider only L(X,Y) = ∥X − Y ∥, the Euclidian
distance in Rp.
In the context of microarray data, a parametric multi-
variate rotation gene set test (ROAST) became popular
for the self-contained GSA approaches [29]. ROAST
uses the framework of linear models and tests whether,
for all genes in a set, a particular contrast of the coeffi-
cients is non-zero [29]. It accounts for correlations bet-
ween genes and has the flexibility of using different
alternative hypotheses, testing whether the direction of
changes for a gene in a set is up, down or mixed (up or
down) [29]. For all comparisons implemented here the
mixed hypothesis was selected. Applying ROAST to
RNA-Seq data requires count normalization first. The
VOOM normalization [7] was proposed specifically for
this purpose where log counts, normalized for sequence
depth, are used. In addition to counts normalization,
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can be incorporated into the linear modeling process
within ROAST to eliminate the mean-variance trend in
the normalized counts [7]. Considering that this feature
is suited specifically for ROAST, we apply VOOM
normalization with ROAST and do not apply any other
normalization (except normalizing for gene length, see
below).
Combining P-values obtained using univariate tests for
RNA-Seq
One way of designing a GSA test is to combine univariate
statistics for individual genes [11,18]; we refer to this tech-
nique as ‘gene-level GSA’ in what follows. There are two
popular univariate tests specifically designed for RNA-Seq
data that rely on Negative Binomial model for read counts:
edgeR [3] and DESeq [4]. Empirical Bayes method (eBayes
[6]) correctly identifies hypervariable genes in the context
of microarray data and, when adapted for RNA-Seq data
through VOOM normalization [7], should be a powerful
approach. Thus, in our comparative power analysis of
gene-level GSA approaches, we include the following uni-
variate tests: edgeR, DESeq, and eBayes. It should be noted
that RNA-Seq counts are normalized for each test based
on its recommended normalization method only.
The key question in designing a gene-level GSA test is
how to combine statistics (P-values) from individual
genes into a single gene set score (P-value). The problem
of combining P-values has been recognized and studied
for a long time (Fisher’s combining probabilities test
[27]). Many methods for combining P-values are avail-
able and can usually be expressed in a form of T = ∑iH
(pi), where P-vales are transformed by a function H [32].
In particular, Fisher’s method (FM) uses H(pi) = − 2ln(pi)
and Stouffer’s method (SM) uses H to be the inverse
normal distribution function [28].
Gamma Method (GM) is based on summing the trans-
formed gene-level P-values using an inverse gamma
cumulative distribution function G−1w;1 where w is the
shape parameter, i.e. the combined test statistic is given by
T ¼PiG−1w;1 1−pið Þ [33]. The shape parameter w controls
the amount of emphasis given to gene-level P-values below
a particular threshold. This feature is imposed by any trans-
formation function H and is referred to as soft truncation
threshold (STT) [33]. It is useful when there is pronounced
heterogeneity in effects. The STT is controlled by w such
that w ¼ G−1w;1 1−STTð Þ . When w is large, GM becomes
equivalent to the inverse normal Stouffer’s method which
has STT = 0.5, and when it is 1 it becomes equivalent to
Fisher’s method with STT = 1/e. Fridley et al. examined the
performance of GM with various STT values and reported
that STT values between 0.01 and 0.36 tend to give the best
power [25]. For our study we chose w = 0.0137 that givesSTT = 0.5. (For more detailed description of the methods
for combining P-values see Additional file 1).
Approaches to normalize RNA-Seq data before applying
multivariate tests
Similar to microarray data [34,35], RNA-Seq data
should be properly normalized before any further sta-
tistical tests can be applied. Raw counts are neither
directly comparable between genes within one sample,
nor between samples for the same gene. The counts of
each gene are expected to be proportional to both gene
abundance and gene length because longer genes pro-
duce more reads in the sequencing process. The counts
will also vary between samples as a result of differences
in the total number of mapped counts per sample
(library size or sequencing depth). The first nor-
malization for RNA-Seq data, ‘reads per kilobase per
million’ (RPKM), was suggested by Mortazavi et al. [36]
and was supposed to guard against over-detection of
longer and more highly expressed genes. Recently,
it was found that RPKM tends to identify weakly
expressed genes as differentially expressed [37] and is
not able to remove the length bias properly [19,37].
Oshlack and Wakefield [38] have demonstrated that
the t-test power has a dependency on the square root
of gene length even after RPKM normalization. While
RPKM remains very popular, a number of other nor-
malizations were suggested [4,39-41]. We employed
three frequently used RNA-Seq normalization stra-
tegies to examine the performance of multivariate tests:
the read per kilobase per million (RPKM) [36], the
quantile-quantile normalization (QQN) [40], and the
trimmed mean of M-values (TMM) [39]. Since both
QQN and TMM ignore gene lengths, they are followed
by RPKM to account for within-sample differences (see
Additional file 1).
Instead of searching for better normalization, an alter-
native way of analyzing RNA-Seq data is to find a count
data transformation such that all approaches developed
for microarray data will become applicable [7]. It was
shown that log counts, normalized for sequence depth,
serve perfectly for this purpose when finding DE genes
(VOOM [7] function in the limma package [6]). Since
VOOM achieves between-samples normalization only,
we followed it with RPKM normalization to account
for gene length differences. VOOM returns normalized
data in a log scale, so, before applying the RPKM
normalization, the data were back-transformed to a
linear scale.
Importantly, none of these normalizations (except
RPKM for GO analysis [19]) have been tested in the
context of GSA approaches. Here we provide the com-
parative power analysis of multivariate GSA approaches
relying on the four aforementioned normalizations.
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The null distribution of the test statistics used for the
WW, KS, and N-statistic tests are estimated using sample
permutations where sample phenotype labels (X and Y)
are permuted randomly and the test statistic is calculated
many times. To get reasonable estimates here this process
was repeated 1,000 times. The empirical estimate of a
P-value for a gene set is then taken as the proportion of
permutations yielding a test statistic more extreme than
the observed one from the original gene set. The same
procedure was employed to compute the combined
P-value Pc for a gene set after gene-level P-values are
transformed and combined. This is necessary due to the
lack of independence between genes which renders the
parametric approach inaccurate.
Biological data and pathways
We analyzed the subset of the data from Pickrell et al.
[42], the sequenced RNA from lymphoblastoid cell lines
(LCL) in 69 Nigerian individuals. We selected 58 unrelated
individuals (parents), 29 males and 29 females. Pickrell
et al. [42] dataset (the ‘Nigerian dataset’ in what follows)
is attractive because there are two natural sets of True
Positives: genes that are escaping X-chromosome inacti-
vation and are therefore overexpressed in females (XiE),
and genes that are located on male-specific region of Y
chromosome and are therefore overexpressed in males
(msY). The dataset also contains a natural set of False Pos-
itives: all X-linked genes that are not escaping inactivation
(Xi, 387 genes after filtering). See Additional file 1 for
more details.
Gene counts were obtained by detecting the overlaps
between mapped short reads and the list of genomic
ranges (of exons) under each gene using the Biocon-
ductor GenomicRanges package (version 1.12.5). Short
reads, which have non-unique mappings, were discarded.
After filtering, the resulting count matrix had a total of
13,191 annotated genes and 58 samples. The normalized
counts were transformed to log-scale using the function
log2(1 + Yij) to further reduce the effects of outliers. (For
more detailed description of the Pickrell et al. [42] data
preprocessing steps see Additional file 1).
Except Xi, msY, and XiE other gene sets were taken
from the C2 pathways set of the molecular signature
database (MSigDB) [43]. These gene sets were curated
from online databases, biomedical literature, and know-
ledge of domain experts. Genes not present in the fil-
tered dataset were discarded, and only pathways with
the number of genes (p) in the range of 10 ≤ p ≤ 500
were included. The resulted dataset comprised 12,051
genes and 4,020 pathways. One C2 pathway, DISTE-
CHE_ESCAPED_FROM_X_INACTIVATION (DEX), con-
tains 13 X-linked genes found in our filtered dataset that
were reported to escape inactivation [44]. While we can’tbe sure if the other C2 pathways are differentially ex-
pressed between males and females, we expect that at least
the three aforementioned pathways (msY, XiE and DEX)
should be, and the Xi pathway should not be detected by
any GSA test. Additional file 2 provides lists of all the
genes and their descriptions in msY, XiE, DEX and Xi
gene sets.
Simulation of RNA-Seq counts
We model the count for a gene i in sample j by a ran-
dom variable Yij from Negative Binomial (NB) distribu-
tion Yij ~NB(mean = μij, var = μij(1 + μijφij)) =NB(μij, φij),
where μij and φij are respectively the mean count and
dispersion parameter of gene i in sample j. For each
gene in a gene set, a vector of mean counts, dispersion,
and gene length information (μi, φi, Li), is randomly se-
lected from a pool of vectors derived from the processed
Nigerian dataset (see Additional file 1). The dispersion
parameter for each gene was estimated using the Biocon-
ductor package edgeR (version 3.4.2) by the empirical
Bayes method [45]. Counts, normalized using different ap-
proaches, were transformed to log-scale using the trans-
formation function log2(1 + Yij) to further reduce the
effects of outliers. Additional file 3: Figure S2 and S3 show
the density and histogram plots for the original counts
and NB simulated counts before and after different nor-
malizations. The simulated counts match the original
counts reasonably well.
To evaluate the tests performance as accurately as
possible, simulation experiments should mimic real ex-
pression data as closely as possible. In a real biological
setting, not all genes in a gene set are differentially
expressed, and the fold changes of genes between diffe-
rent phenotypes can vary. Therefore, we introduced two
parameters: γ, the percentage of genes truly differentially
expressed in a gene set; and FC, the amount of fold
change in gene counts between two phenotypes. These
parameters are expected to influence the power of diffe-
rent tests on a different scale. For the γ parameter, we
consider γ∈{1/8, 1/4, 1/2}, and for the parameter FC, the
values span the range from 1.2 to 3. Using simulations
we assess the detection power for all tests by testing the
hypothesis H0: μx = μy (or H0: FC = 1) against an alterna-
tive H1: μx ≠ μy (or H1: FC ≠ 1).
We simulated two datasets of equal sample size, N/2
(N = 20 and N = 40) forming 1,000 non-overlapping gene
sets, each constructed from p random realizations of NB
distribution. These two datasets represent two biological
conditions with different outcomes. For a gene set in
one phenotype, we generate p random realizations of
NB distribution with parameters (μi, φi). For the same
gene set in the second phenotype, we generate NB reali-
zations with parameters (FC μi, φi) when i ≤ γp repre-
sents DE genes and NB realizations with parameters
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were considered in our simulations: when the number of
genes in a gene set is relatively small (p = 16) or when
the number is relatively large (p = 100). To avoid having
all the DE genes up-regulated for all generated gene sets
in one phenotype, we swapped the generated counts for
half of the DE genes (1 ≤ i ≤ γp/2) between the two phe-
notypes. Hence, now in each generated gene set, half of
the DE genes are up-regulated and half are down-
regulated between the two phenotypes. This will also
avoid the problem of having large differences in total
counts per sample between the two phenotypes.
To estimate the Type I error rates for all tests using sim-
ulated count data, we set FC and γ to 1 and simulated two
datasets of equal sample size, N/2 (N∈{20,40,60}) from
1,000 gene sets, each constructed form p random realiza-
tions of Negative Binomial distribution with parameters
(μi, φi) where p∈{16,60,100}. Then, we estimate the pro-
portion of gene sets that reject H0: μx = μy (or H0: FC = 1)
among the 1,000 generated sets.
Results
Simulation study
Type I error rate
Table 1 presents the estimates of the attained significant
levels for the multivariate tests with different normaliza-
tions. As expected as the sample size N increases, the
Type I error rates decrease. When the sample size is
small (N = 20), N-statistic with VOOM normalization
gives the most conservative Type I error rate, followed
by ROAST (for p = 16, 60). This can be explained by
VOOM’s ability to model the mean-variance relationship
of count data for small N. But when the sample size is
larger, TMM almost always gives more conservative esti-
mates than VOOM (except when N = 60, p = 100). WWTable 1 Type I error rates for multivariate methods, α = 0.05
p = 16 p = 60
RPKM QQN TMM VOOM RPKM
N = 20 N-stat 0.060 0.062 0.038 0.038 0.054
WW 0.096 0.103 0.091 0.091 0.102
KS 0.104 0.090 0.083 0.082 0.102
ROAST 0.050
N = 40 N 0.053 0.048 0.049 0.048 0.058
WW 0.066 0.075 0.063 0.073 0.060
KS 0.069 0.071 0.072 0.073 0.068
ROAST 0.052
N = 60 N 0.052 0.054 0.060 0.067 0.051
WW 0.089 0.066 0.065 0.079 0.057
KS 0.061 0.073 0.055 0.060 0.052
ROAST 0.054seems to be the most liberal among multivariate tests,
followed by KS. For every test the Type I error rate is
virtually unaffected when the number of genes in a path-
way (p) increases.
We next consider Type I error rates for gene-level
GSA tests that use univariate RNA-Seq specific tests
(edgeR, DESeq and eBayes) and employ different me-
thods for combining P-values (FM, SM and GM with
STT = 0.05). To better understand the functional rela-
tionship between the transformed and the original
P-values we applied the transformation functions H
(used by FM, SM and GM with STT = 0.05) to a range
of P-values (P-value is changing from 10−5 to 1 with the
step of 10−5, Figure 1).
Figure 1 shows interesting biases that are introduced
by different transformations (FM, SM and GM). First,
GM is only sensitive to the extremely small P-values and
virtually ignores all the others. In practice it means that
gene sets with a large number of genes will be called DE
by tests with GM more frequently than gene sets with a
small number of genes. This is expected because, by
pure chance alone, gene sets with a large number of
genes have higher probability to contain genes with ex-
tremely small P-values, and GM ignores all the others.
Second, FM accounts not only for the extremely small
P-values, but also for generally small P-values, as well as
large P-values. Therefore, tests with FM would call a
gene set DE if and only if most of the genes in a gene
set have small P-values. Gene sets with a large number
of genes will be called DE by tests with FM less fre-
quently than gene sets with a small number of genes,
because, again, by pure chance alone, gene sets with a
large number of genes have higher probability to contain
genes with large P-values and large P-values affect the
FM score (Figure 1). Third, unlike FM and GM, SMp = 100
QQN TMM VOOM RPKM QQN TMM VOOM
0.062 0.058 0.035 0.052 0.050 0.049 0.047
0.102 0.096 0.070 0.097 0.099 0.099 0.089
0.088 0.077 0.076 0.080 0.077 0.072 0.092
0.048 0.036
0.052 0.035 0.048 0.054 0.047 0.039 0.051
0.058 0.056 0.076 0.056 0.067 0.067 0.079
0.079 0.059 0.059 0.055 0.066 0.081 0.065
0.050 0.039
0.040 0.053 0.055 0.046 0.054 0.059 0.044
0.069 0.060 0.073 0.065 0.065 0.076 0.064
0.059 0.061 0.070 0.053 0.051 0.068 0.047
0.043 0.055
Figure 1 The functional relationship between the transformed and the original P-values for different transformation functions H (used
by FM, SM and GM with STT = 0.05).
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http://www.biomedcentral.com/1471-2105/15/397maps P-values less than 0.5 and greater than 0.5 to posi-
tive and negative values with magnitudes depending on
the deviation from 0.5 (Figure 1). As a result tests with
SM would call a gene set DE if and only if all genes in a
set have small P-values. Similar to tests with FM, tests
with SM are expected to call DE gene sets with a small
number of genes.
The simulation results clearly demonstrate that the Type
I error rates are influenced by the aforementioned biases
introduced by different transformation functions (FM, SM
and GM). As expected, for all gene-level GSA approaches
that use univariate tests and different transformationTable 2 Type I error rates for gene-level GSA methods, α = 0.0
p = 16 p = 60
edgeR DESeq eBayes edgeR
N = 20 FM 0.087 0.067 0.045 0.107
SM 0.052 0.048 0.045 0.063
GM 0.123 0.092 0.049 0.187
N = 40 FM 0.067 0.058 0.049 0.082
SM 0.065 0.062 0.054 0.059
GM 0.092 0.063 0.051 0.132
N = 60 FM 0.066 0.061 0.048 0.056
SM 0.052 0.047 0.046 0.048
GM 0.088 0.072 0.049 0.090functions to combine P-values, tests with GM show the
highest Type I error, followed by tests with FM and SM
(Table 2, Figure 1). Also, for any P-values combining
method, edgeR shows the highest Type I error, followed
by DESeq and eBayes respectively. In addition, with GM
transformation, when the number of genes in a gene set
(p) increases, especially for edgeR and DESeq, the Type I
error rate becomes extremely high.
The power to detect shift alternatives
Figure 2 presents the power estimates for the N-statistic,
WW and KS multivariate tests with different normalizations5
p = 100
DESeq eBayes edgeR DESeq eBayes
0.072 0.046 0.096 0.065 0.037
0.062 0.048 0.046 0.047 0.040
0.141 0.039 0.245 0.180 0.041
0.059 0.049 0.090 0.073 0.054
0.060 0.053 0.063 0.061 0.057
0.091 0.058 0.164 0.104 0.051
0.050 0.049 0.072 0.061 0.044
0.050 0.049 0.048 0.046 0.058
0.065 0.050 0.108 0.091 0.046
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Figure 2 The power curves of multivariate tests with different normalizations when shift alternative hypothesis (H1) holds true and the
number of genes in pathways p = 16 (N = 20).
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http://www.biomedcentral.com/1471-2105/15/397and ROAST with only VOOM followed by RPKM nor-
malization (see Section Multivariate tests), when H1: μx ≠ μy
is true (N = 20, p = 16). It appears that ROAST outper-
forms all the other approaches followed respectively bythe N-statistic, WW, and KS. Different normalizations do
not affect the tests’ power at all (Figure 2). When N = 20
and p = 100 (Additional file 3: Figure S3), N = 40 and
p = 16 (Additional file 3: Figure S4), N = 40 and p = 100
Rahmatallah et al. BMC Bioinformatics 2014, 15:397 Page 9 of 15
http://www.biomedcentral.com/1471-2105/15/397(Additional file 3: Figure S5) the results are similar, but
the power to detect even small fold changes is higher
for all tests.
Figure 3 presents the power estimates for gene-level
























































































Figure 3 The power curves of gene-level GSA methods when shift alt
pathways p = 16 (N = 20).and eBayes) and employ different methods for combi-
ning P-values (FM, SM, and GM with STT = 0.05) when
H1 is true (N = 20, p = 16). When the percentage of truly
differentially expressed genes is small (γ = 1/8), all three
tests that apply GM have slightly higher power than2.0 2.5 3.0
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ernative hypothesis (H1) holds true and the number of genes in
Table 3 Average type I error rates attained from Nigerian
male samples, α = 0.05
RPKM QQN TMM VOOM
N-stat 0.049 0.045 0.044 0.055
WW 0.069 0.062 0.058 0.072
KS 0.052 0.052 0.048 0.059
ROAST 0.033
FM SM GM
edgeR 0.075 0.062 0.119
DESeq 0.068 0.059 0.103
eBayes 0.059 0.057 0.063
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http://www.biomedcentral.com/1471-2105/15/397those tests with FM, while the power of tests with SM is
much smaller. When γ increases (from the top to the
bottom on each panel of Figure 3) the difference bet-
ween tests with GM and tests with FM diminishes, and
the power of tests with SM becomes very close to
the power of tests with FM and GM. The results when
N = 20 and p = 100 (Additional file 3: Figure S6), N = 40
and p = 16 (Additional file 3: Figure S7) and N = 40 and
p = 100 (Additional file 3: Figure S8) are similar, but the
power to detect even small fold changes is higher for all
tests. Comparing the performance of the three univariate
tests under each P-value combining method shows that
edgeR has slightly higher power than DESeq and eBayes,
with both FM and GM, while eBayes has slightly higher
power than edgeR and DESeq with SM (Additional file 3:
Figure S9). Additional file 3: Figure S10 (N = 20 and
p = 100), Additional file 3: Figure S11 (N = 40 and p = 16),
and Additional file 3: Figure S12 (N = 40 and p = 100)
demonstrate a similar pattern with even more insignificant
differences.
To summarize, Figures 2 and 3 demonstrate, that
when a gene set has only a few differentially expressed
genes (γ = 1/8), edgeR (with GM or FM) has a higher
power to detect very small fold changes than the other
multivariate and gene-level GSA methods. However,
when γ = 1/4 and γ = 1/2, ROAST has the same power
as edgeR with GM or FM. It should be noted that the
higher power of edgeR with GM or FM is caused by the
higher Type I error of edgeR with GM or FM (Table 2
and see below).
The analysis of the Nigerian dataset
Type I error rate
To estimate how different tests control the Type I error
rate for the real data, we performed intra-condition com-
parisons using only male samples from the Nigerian data-
set. The male samples were randomly distributed over two
groups, and GSA was conducted using all tests over C2
pathways from the MSigDB [43] database. There should
be no gene sets differentially expressed between these two
groups. The Type I error rate was averaged over 100 sam-
ple permutations (Table 3). For multivariate tests, ROAST
has the lowest average Type I error rate, followed by
N-statistic, KS and WW. Similar to the simulated data
when the sample size is large, for real data TMM and
QQN normalizations have lower average Type I errors
than RPKM and VOOM.
Interestingly, for gene-level GSA tests with different
P-values transformations (FM, SM, GM), the Type I error
rate estimates on real data mimic exactly the Type I error
rate estimates on simulated data (Tables 1 and 2). All
three tests (edgeR, DESeq, and eBayes) that apply GM
show the highest Type I error followed by tests with FM
and SM respectively. Under each P-value’s combiningmethod, edgeR has the highest Type I error rate, followed
by DESeq and eBayes.
The Type I error rate estimates on real and simulated
data are perfectly correlated for gene-level GSA tests.
For real data and multivariate tests, TMM and QQN
normalizations lead to the more conservative Type I
error rate estimates.
Detected pathways
While, for real data, the Type I error rate of different
GSA approaches can be directly evaluated by using two
subsets from the same group, there is no straightforward
and unbiased way to evaluate their power. We selected
the Nigerian dataset [42] because it contains two sets of
True Positives: genes that are escaping X-chromosome
inactivation and are therefore overexpressed in females
(XiE), and genes that are located on male-specific region
of Y chromosome and are therefore overexpressed in
males (msY). All tests detect msY, XiE, and DEX (C2
pathway, containing X-linked genes escaping inacti-
vation) with high significance. All tests fail to detect Xi
(all X-linked genes that are not escaping inactivation)
except for the univariate tests with GM, because univa-
riate tests with GM have the highest Type I error rate
(see Additional file 1: Table S3).
Except for pathways containing gender-specific genes,
there is no set of pathways that are guaranteed to be dif-
ferentially expressed between male and female samples.
We therefore decided to examine the entire set of C2
pathways with the goal to quantitatively characterize dif-
ferent methods based on: (1) a number of detected path-
ways at the different significance levels; (2) the average
number of genes in detected pathways; (3) the average
length of genes in detected pathways; and (4) the per-
centage of differentially expressed genes in detected
pathways. This information will clarify whether there are
methods that are: (1) overlay liberal (detect too many
pathways that are not shared with the majority of the
other approaches); (2) biased in terms of the number of
genes in detected pathways; (3) biased in terms of the
Rahmatallah et al. BMC Bioinformatics 2014, 15:397 Page 11 of 15
http://www.biomedcentral.com/1471-2105/15/397average gene length in detected pathways; or (4) detect-
ing only pathways with small (large) number of differen-
tially expressed genes.
Among multivariate tests WW is the most liberal (343
with RPKM, 352 with QQN, 333 with TMM and 348 with
VOOM). KS is the next most liberal (267 with RPKM,
292 with QNN, 278 with TMM and 271 with VOOM).
N-statistic is more conservative than both WW and KS
(241 with RPKM, 254 with QNN, 252 with TMM and 245
with VOOM). ROAST is the most conservative among
multivariate tests (199 pathways). Methods with QQN
normalization detect slightly more pathways as compared
to the same method with other normalizations.
Univariate tests with GM detect by far the highest
number of pathways (603 with edgeR, 565 with DESeq,






























































































Figure 4 Venn diagrams showing the number of common pathways d
with normalizations and univariate tests with combined P-values for
normalizations and ROAST; (b) WW with different normalizations and ROAS
different P-values combining methods; (e) DESeq with different P-values co
methods; (g) univariate tests with FM; (h) univariate tests with SM; (i) univaconservative among methods (63 with edgeR, 56 with
DESeq, and 77 with eBayes), followed by FM (151 with
edgeR, 162 with DESeq, and 146 with eBayes). These ob-
servations are in agreement with the Type I error rate
estimates for univariate tests with different approaches
for combining P-values (Tables 2 and 3).
The Venn diagrams in Figure 4 show the common path-
ways detected (α = 0.05) by multivariate tests with dif-
ferent normalizations (except ROAST which uses VOOM
followed by RPKM only) and univariate tests with dif-
ferent P-values combining approaches. N-statistic detects
more common pathways with ROAST than WW and KS
and also has more common pathways across different nor-
malizations (Figure 4a). Both WW and KS have much
more unique pathways detected by one normalization

















































































etected in the processed Nigerian dataset by multivariate tests
gene-level GSA methods (α = 0.05). (a) N-statistic with different
T; (c) KS with different normalizations and ROAST; (d) edgeR with
mbining methods; (f) eBayes with different P-values combining
riate tests with GM.
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http://www.biomedcentral.com/1471-2105/15/397only highly significant pathways are detected, conse-
quently, WW and KS now show similar common groups
with ROAST (Additional file 3: Figure S13).
Univariate tests with different P-values combining
methods have very small overlap between pathways
detected by different approaches (Figure 4d,e,f ), as com-
pared to multivariate tests. The overlap between path-
ways detected by different univariate tests with the same
P-value combining method (Figure 4g,h,i) is larger than
the overlap between pathways detected by the same
univariate test with different methods for combining
P-values (Figure 4d,e,f ). This demonstrates that the
P-value combining method is the more important factor
than the test itself in detecting DE pathways.
Figure 5 shows the number of genes, the percentage of
DE genes, and the average gene length in detected path-
ways for all tests (α = 0.05). The DE genes in each path-
way were found using eBayes. Figure 5 confirms the
presence of biases in gene-level tests for GSA that are
introduced by different P-value combining approaches.
Tests with SM and FM favor pathways with a small
number of genes and require larger percentages of DE
genes in order to detect a pathway. On the contrary tests
with GM favor pathways with a large number of genes
and require less percentage of DE genes to detect a
pathway.Figure 5 The percentage of DE genes, number of genes and average
dataset by different methods.To test whether there are methods that detect path-
ways with average gene lengths significantly different
than the average gene length of all 4020 C2 pathways,
Wilcoxon’s non-parametric test was applied. All univa-
riate tests with GM, eBayes with SM, and WW with any
normalization, detect pathways with longer genes than
the average. The deviation found in eBayes with SM can
be attributed to a small number of detected pathways
with a small number of genes, which doesn’t allow
accurate estimation of the average gene length per
detected pathways. On the other hand, tests with GM
detect a large number of pathways with a large number
of genes, and it also makes the estimate of the average
gene length per detected pathway biased.
Discussion
Here we have presented a comparative power and Type I
error rate analyses for self-contained GSA approaches that
could be possibly used for RNA-Seq data. In contrast to
microarrays, RNA-Seq data consists of discrete counts,
therefore GSA approaches developed for microarrays are
not directly applicable to RNA-Seq. We have evaluated and
compared three multivariate non-parametric approaches
(N-statistic, Kolmogorov-Smirnov, and Wald-Wolfowitz
tests) in combination with four different normalizations
(RPKM, TMM, QNN, and VOOM), ROAST, [29] andgene length in detected pathways in the processed Nigerian
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specific tests (edgeR, DESeq, and eBayes) and employed
different methods for combining P-values (FM, SM,
and GM). In sum we analyzed the performance of twenty-
two combinations of tests, including normalization and
P-value combining methods in the analysis of RNA-Seq
data. All approaches were evaluated on simulated and real
data, and their significance was evaluated from sample
permutations.
We found that for simulated data the Type I error rate
and the power of different multivariate approaches in
combination with four different normalizations were
virtually unaffected by different normalizations. It should
be noted that the Type I error rate was only slightly (in
the range of 0.01 for the same multivariate test) affected
by the normalization used, while the power was not
affected at all. Expectedly, both measures were seriously
affected by different test statistics. The best-performing
approach, in terms of the smallest Type I error rate and
the largest power, when the percentage of truly DE
expressed genes in a pathway (γ) and a fold change
(FC) were small, was ROAST [29], closely followed by
N-statistic. Multivariate non-parametric Wald-Wolfowitz
and Kolmogorov-Smirnov had the smallest power and the
largest Type I error rates with all normalizations. The
Type I error rate estimates on real data reproduced the
trends observed on simulated data. Again, ROAST was
the most conservative approach among multivariate tests,
and different normalizations didn’t affect the Type I error
rates as much as the different test statistics. All of the tests
were able to detect gender-specific pathways (msY, XiE
and DEX) as differentially expressed between male and
female samples with high significance. Xi was not detected
by any test.
We also examined the entire set of C2 pathways to
quantitatively characterize different methods. The analysis
of all C2 pathways confirmed that ROAST is the most
conservative among multivariate tests, having the least
amount of DE pathways detected. Similarly to the simu-
lated data, ROAST was closely followed by N-statistic.
Again, for real data, only multivariate test statistics and
not normalizations influenced the results to a measurable
extent. Thus, on simulated and real data, in terms of
the Type I error rate and power, ROAST and N-statistic
outperformed all other tests, independently of the nor-
malization used. We did not find any evidence of bias for
multivariate tests in terms of the number of genes, or the
percentage of DE genes in detected pathways with any
type of normalization. Surprisingly, among all multivariate
tests, multivariate non-parametric Wald-Wolfowitz with
any normalization detected pathways with longer genes
than the average. It might be related to the fact that WW
was the most liberal test among all multivariate tests
considered.For the simulated data, gene-level tests for GSA were
heavily dependent on the method used for combining
P-values, and the differences in power and Type I error
rate between univariate tests with the same approach for
combining P-values were much smaller than the dif-
ferences when the same test, but different combining
P-values approaches, were applied. When the percentage
of truly differentially expressed genes (γ) and fold
changes were small, all three tests (edgeR, DESeq, and
eBayes) with GM outperformed tests with FM and SM.
This difference disappeared when γ increased.
For gene-level tests for GSA, it appeared that trends in
Type I error rates, estimated from real data, were again
similar to the trends in simulated data. All gene-level
tests for GSA detected gender-specific pathways, but, in
addition, all tests with GM detected the Xi pathway that
should not be detected. For gene-level tests for GSA, the
analysis of all C2 pathways shows that all of them (ex-
cept tests with GM) have very small overlap between
pathways detected by different approaches as compared
to multivariate tests. The overlap between pathways de-
tected by different univariate tests with the same method
for combining P-values was larger than the overlap bet-
ween pathways detected by the same univariate test with
different methods for combining P-values, but still in an
order of magnitude smaller than for multivariate tests
(excluding tests with GM, see below). This indicates
that, first, the P-values combining method is the leading
factor in detecting DE pathways using gene-level tests
for GSA, and, second, for real data they have less power
than multivariate approaches in an order of magnitude.
The analysis of C2 pathways on the Nigerian data con-
firmed our expectations, which were formed by the ana-
lysis of the functional dependencies between the original
and transformed P-values for different P-values combi-
ning methods (Figure 1). All tests with GM exclusively
detected pathways with a large number of genes and a
small percentage of DE genes as compared to the other
approaches. All tests with SM exclusively detected path-
ways with a small number of genes and a large percen-
tage of DE genes as compared to the other approaches.
The Type I error rate, the number of genes and the per-
centage of DE genes necessary to detect a pathway for
all tests with FM, were exactly in-between GM and SM:
smaller than for all tests with GM and larger than for all
tests with SM. In agreement tests with GM and eBayes
with SM all detected pathways with longer genes than
the average (Wilcoxon’s test, Figure 5).
The results from simulated and real data show that
gene-level tests for GSA with GM have the highest Type
I error rates and the highest power. In addition all tests
with GM had the highest number of genes and the smal-
lest percentage of truly DE genes in detected C2 path-
ways. These observations indicate that the gain in power
Rahmatallah et al. BMC Bioinformatics 2014, 15:397 Page 14 of 15
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Tests with SM had the smallest power and the smallest
Type I error rates, while the results for tests with FM
were intermediate.
It should be noted that recently edgeR with GM was
found to outperform many other approaches for GSA in
terms of power and Type I error rate and was recom-
mended for RNA-Seq data analysis [25]. Indeed, we ob-
served that edgeR with GM had the highest power
among all the other approaches. In a recent publication
edgeR with GM was suggested to be the first method of
choice for GSA of RNA-Seq data [25]. In contrast to this
result, our study showed that for simulated and real data
edgeR with GM has the highest Type I error rate among
all the other tests for GSA. We hypothesize that the dif-
ference between the two studies stems from the way the
data were simulated. In our study we used the Negative
Binomial model, which is used in edgeR for finding DE
genes. In [25] the multivariate normal distribution with
fixed correlation structure was used, but, surprisingly,
edgeR was used for finding DE genes. Therefore, in the
latter case, the distributional assumption of the method
(edgeR) was not met, which could have led to the bias in
the estimation of the Type I error rates. However, all
simulations are only crude approximations of biological
reality. To estimate the Type I error rates on the real
data, we performed intra-condition comparisons using
only male samples from the Nigerian dataset: there
should not be gene sets differentially expressed between
these two groups. Again, edgeR with GM had the high-
est Type I error rate for real data among all other tests,
confirming that in contrast with [25] results, edgeR with
GM has inadequate control of the Type I error rate.Conclusions
Overall, for the self-contained category of GSA, multi-
variate GSA tests are insensitive to different normali-
zations and have better control of Type I error rates
and higher power as compared to gene-level GSA tests,
both on simulated and real data. In addition, while
standard gene set over-representation analysis shows as
over-represented categories with longer genes [19],
standard multivariate GSA tests (except WW) with dif-
ferent normalizations do not have any biases in terms
of the pathway size, the percentage of DE genes, or the
average gene length in a pathway. The opposite is true
for all gene-level GSA tests. Thus, our study argues
against the use of gene-level tests for GSA whether
with Fisher’s combining probabilities Method [27], or
Stouffer’s Method [28], or the soft thresholding Gamma
Method [25], and emphasize the importance of using
non-parametric multivariate tests for detecting DE
pathways for RNA-Seq data.Availability of software
Software implementing the multivariate generalizations
of the Kolmogorov-Smirnov and Wald-Wolfowitz tests
in R was released within the GSAR package in ver-
sion 3.0 of Bioconductor (http://www.bioconductor.org/
packages/release/bioc/html/GSAR.html).
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